Inhibition of rat liver fibrogenesis through noradrenergic antagonism
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
The effect of adrenergic innervation and/or circulating catecholamines on the function of liver fibrogenic cells is poorly understood. Our aim was to investigate the effects of noradrenergic antagonism on carbon tetrachloride (CCl 4)-induced liver fibrosis in rats. Two weeks of CCl 4 induced a ˜5-fold increase in the area of fibrosis as compared with controls. The addition of 6-hydroxydopamine (OHDA), a toxin that destroys noradrenergic fibers, decreased fibrosis by 60%. After 6 weeks of CCl 4, the area of fibrosis increased about 30-fold in CCl 4-treated animals and was decreased by 36% with OHDA. At 2 weeks, OHDA abrogated the CCl 4-induced increase in mRNA level of tissue inhibitor of matrix metalloproteinases-1 (TIMP-1), an inhibitor of extracellular matrix degradation, and it greatly reduced it at 6 weeks. Finally, when rats treated with CCl 4 for 2 weeks also received prazosin, an antagonist of α 1-adrenergic receptors, fibrosis was decreased by 83%. In conclusion, destruction of noradrenergic fibers or antagonism of noradrenergic signaling through α 1 receptors inhibited the development of liver fibrosis. Because adrenoreceptor antagonists have a very sound safety profile, they appear as attractive drugs to reduce liver fibrogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Expression of tissue inhibitor of metalloproteinases 1 and 2 is increased in fibrotic human liver
Benyon, R., Iredale, J., Goddard, S., Winwood, P., & Arthur, M. (1996) · Gastroenterology · doi:10.1053/gast.1996.v110.pm8608892 · Cited by 353
Iredale, J. P., Benyon, R. C., Arthur, M. J., Ferris, W. F., Alcolado, R., Winwood, P. J., Clark, N., & Murphy, G. (1996) · Hepatology · doi:10.1002/hep.510240129 · Cited by 324
Wong, L., Yamasaki, G., Johnson, R. J., & Friedman, S. L. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117497 · Cited by 304
Demonstration of noradrenaline-immunoreactive nerve fibres in the liver
Fukuda, Y., Imoto, M., Koyama, Y., Miyazawa, Y., & Hayakawa, T. (1996) · Journal of International Medical Research · doi:10.1177/030006059602400603 · Cited by 40
Cited by
Hemmann, S., Graf, J., Roderfeld, M., & Roeb, E. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.02.003 · Cited by 509
Desmoulière, A., Darby, I. A., & Gabbiani, G. (2003) · Laboratory Investigation · doi:10.1097/01.lab.0000101911.53973.90 · Cited by 363
Self-citationThe myofibroblast, a key cell in normal and pathological tissue repair
Darby, I. A., Zakuan, N., Billet, F., & Desmoulière, A. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2110-0 · Cited by 328
Self-citationHepatic fibrosis: molecular mechanisms and drug targets
Lotersztajn, S., Julien, B., Teixeira-Clerc, F., Grenard, P., & Mallat, A. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095906 · Cited by 325
Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis
Kral, J. G., Thung, S. N., Biron, S., Hould, F.-S., Lebel, S., Marceau, S., Simard, S., & Marceau, P. (2004) · Surgery · doi:10.1016/j.surg.2003.10.003 · Cited by 322
Metadata
- Authors
- Dubuisson, L., Desmoulière, A., Decourt, B., Evadé, L., Bedin, C., Boussarie, L., Barrier, L., Vidaud, M., & Rosenbaum, J.
- Venue
- Hepatology
- Published
- 2002-02
- Volume
- 35
- Issue
- 2
- Pages
- 325-331
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2016219027
- Cited by
- 85
- References
- 4
- FWCI
- 5.09
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhibition of rat liver fibrogenesis through noradrenergic antagonism. https://app.cochat.ai/papers/10.1053/jhep.2002.31166
- The paper
- Dubuisson, L., Desmoulière, A., Decourt, B., Evadé, L., Bedin, C., Boussarie, L., Barrier, L., Vidaud, M., & Rosenbaum, J. (2002). Inhibition of rat liver fibrogenesis through noradrenergic antagonism. Hepatology. https://doi.org/10.1053/jhep.2002.31166
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.